Navigation Links
Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

inducing and maintaining clinical remission in adult and pediatric patients with moderately-to-severely active CD who have had an inadequate response to conventional therapy. REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing CD. In December 2004, REMICADE was approved for reducing signs and symptoms in patients with active AS. In May 2005, REMICADE was approved for reducing signs and symptoms of active arthritis in patients with PsA. Additionally, in September 2005, REMICADE was approved for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy. This approval makes REMICADE the first and only biologic approved for the treatment of moderate to severe UC. In May 2006, REMICADE was approved for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. This approval establishes REMICADE as the first and only biologic therapy approved for the treatment of PCD. In August 2006, REMICADE was approved for inhibiting progression of structural damage and improving physical function in patients with psoriatic arthritis. In September 2006, REMICADE was approved for the treatment of adults with chronic, severe (i.e. extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. In October 2006, REMICADE was approved for maintaining clinical remission and mucosal healing in patients with moderately to severely active UC, who have had an inadequate response to conventional therapy.

In the EU, REMICADE is indicated for the treatment of severe, active CD in pa
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation
Post Your Comments:
(Date:8/28/2014)... -- Pharmatech initiated enrollment for its AccessPPM program ... for matching cancer patients to cancer clinical trials. ... cancers, disease staging, and genetic mutations - which ... the first place. The challenge that the industry ... well known to the patient or even their ...
(Date:8/28/2014)... , Aug. 28, 2014 Tianyin Pharmaceutical ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today updates the timeline ... Facility (QLF). The Company is ... dataset for China Food & Drug Administration,s (CFDA) ...
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
Breaking Medicine Technology:Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Financial Results Conference Call and Webcast 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:8/28/2014)... 2014 UWDress.com, an internationally famous designer ... unveiled its fashionable assortment of fall bridesmaid dresses ... and old customers, the company is now providing big ... company’s discounted fall bridesmaid outfits are offered in many ... collection are priced less than $190. UWDress.com’s kind officials ...
(Date:8/28/2014)... these particular arguments against the policy, put forward by ... the first country in the world to introduce standardised ... Ireland, and the UK are currently considering similar legislation. ... policy would deter people from buying their tobacco from ... of cheap products sourced from Asia, and increase the ...
(Date:8/28/2014)... Recently, iFitDress.com, the distinguished wedding dress manufacturer and retailer, ... dresses . Included in the new range are hundreds ... are provided at deeply discounted prices, from 22 to ... and reliable delivery service. All clients from around the ... time. As is commonly noted, international customers have different ...
(Date:8/28/2014)... of women who are given information about the chance ... not fully understand the risks involved, according to research ... , today (Friday). , In a survey of around ... London (UCL) found that 64 per cent felt they ... chance that screening will pick up cancers that would ...
(Date:8/28/2014)... 2014 Blood's Thicker Than Water is based ... family ties in the heart of the city. Raymond E. ... story about how disrespect caused two families to collide with ... , The Yayo Boyz and the M.O.B. Boyz clash in ... local onlookers in a silent terror. "Guerrilla," AKA "Real," runs ...
Breaking Medicine News(10 mins):Health News:Fashionable Fall Bridesmaid Dresses From UWDress.com 2Health News:Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco 2Health News:New Selection of Chic Bridesmaid Dresses Available at iFitDress.com 2Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2
... (June 24, 2010) The nerve cell-damaging plaque that ... builds up in the retinas of the eyes ... prospect that noninvasive optical imaging of the eyes could ... disease, according to new research. Scientists discovered characteristic ...
... of large sessile colorectal polyps is increasingly used as ... its technical difficulty, the high risk of complications such ... malignancy. This research, lead by Dr. Sohn DK ... demonstrated the safety of endoscopic piecemeal resection (EPMR) for ...
... may increase the risk of severe asthma attacks among people ... Harvard Medical School, Harvard Pilgrim Health Care Institute and Brigham ... on the American Thoracic Society,s journal Web site ahead of ... and Critical Care Medicine . "We found that the ...
... School of Medicine has received a $5.3 million grant from ... four-year clinical trial to show the effects of weight loss ... co-existing medical conditions in overweight breast cancer survivors. ,This ... study that will examine the effect of weight loss on ...
... coping with stress succumb easily to substance use cravings, ... to behavioral researchers. "Cravings are a strong predictor of ... development, Penn State. "The goal of this study is ... person on a within-day basis. Because recovery must be ...
... A pair of University of California San Diego researchers ... and disorders, and Yang Xu, an immunologist have ... from the California Institute for Regenerative Medicine (CIRM). ... Immunology awards totaling $25 million that were approved at ...
Cached Medicine News:Health News:Hallmark Alzheimer's disease changes found in retinas of humans and imaged in live animals 2Health News:Hallmark Alzheimer's disease changes found in retinas of humans and imaged in live animals 3Health News:Moldy homes a serious risk for severe asthma attacks in some 2Health News:UC San Diego researcher awarded $5.3 million for breast cancer survivorship study 2Health News:Ignoring stress leads recovering addicts to more cravings 2Health News:UCSD researchers receive $2.5 million in new stem cell grants 2
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
... Control is designed to ... significant range of those ... during fertility or pregnancy ... hCG-Beta Subunit levels allow ...
... provides the clinical laboratory with the ... for monitoring immunoassay and therapeutic drug ... separate controls. Made from human serum ... suitable for most methods and is ...
Lyphochek Immunology Plus Control is an assayed control for monitoring chemistry procedures that test for autoimmune, anemic, malignant, hepatic and nephrotic-disease states. Available in two levels....
Medicine Products: